Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

NCT00850577 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

255

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: CT-322
DRUG: Bevacizumab
DRUG: Bevacizumab placebo (ie saline solution)

Sponsor

Bristol-Myers Squibb